WHO Sounds Alert Over Critical Scarcity of Weight-Loss Medications

Less than a tenth of patients that would benefit from GLP-1 drugs such as Wegovy have access to them, warns the global health agency as it publishes its inaugural recommendations on the medications.

Considering over a billion people worldwide now classified as obese, it is calling for broader and more equitable access to GLP-1 medication.

According to estimates, more than two billion are projected to be living with obesity by 2030 without intervention.

"The new guidelines affirms that excess weight is a lifelong illness that can be addressed with holistic and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and supply-chain constraints are significant obstacles to broad access to the jabs that can aid individuals in losing considerable body mass, explains the body.

Skinny Jab Scarcity

Even in the current most optimistic case, the supply of GLP-1 therapies would only suffice for around 100 million people – less than 10% of those who need them, per the health organization.

The recommendation calls on governments and firms to widen availability, by approaches such as patent sharing.

Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is set to lapse in multiple countries in 2026.

How Obesity Injections Operate

These medications replicate a biological compound to reduce digestion speed, curb appetite and boost the sense of being full so users eat less.

Individuals typically see weight reduction in the initial weeks of commencing the regular doses.

Studies suggests people may see weight return after a year of discontinuing the drug, because their typical hunger resume.

To be carrying excess weight raises your likelihood for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some cancers.

Obesity impacts individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.